What will this fall to on failed takeover?, page-59

First 59 Last

Share
Profile

Follow
Taltan

210 Posts.

13

23/11/23

14:28

Post #: 71069633
Share

Originally posted by jm3767: ↑

I think aspects of this whole thing now stinks & lacks transparency to ordinary shareholders...

1. ORG in its announcement said”
Origin also advises that based on the proxy votes received to date, had the Scheme Meeting proceeded today, it is unlikely that the Scheme would have achieved the required 75 per cent approval by shareholders.”.

How come the ORG board/mgt can get access to proxy vote counts PRIOR to the meeting yet this is information is not avail to others or public info.
Unless a shareholder makes public their voting intention, proxy votes should be secret until the poll is held at the meeting.
The current situation just allows the board (who are proponents of & strongly support the deal) to go lobbying for extra support votes should they see the voting to be close or rusk not going the way they wish.
I would like the ORG board to now disclose the proxy vote counts as they currently stand.

2. The ‘revised proposal’ is running roughshod over small and retail investors when it DENYS access to participate as investor in the Brookfield owned ‘Energy Markets’ business after Scheme settles, reserving that option only for INSTITUTIONAL investors.
I may not wish to invest in it, but to me, its treating RETAIL shareholders as ‘second class scum’ with the attitude of “take your pieces of silver” shut up and FOff.

”under the existing Scheme, the addition of a potential opportunity for institutional shareholders to re-invest into the Brookfield owned Energy Markets business after completion of the Scheme”

The retail shareholders should not accept this contemptous treatment.
There are many of us (100k) , and if only say 10-20% vioted & cast a No vote, there is way in the world that they would get the required 50% support of SHAREHOLDERS (HIN) who vote.

It is high time we retail shareholders rose up against the ‘suits in the room’ and at the board table and showed them that we DO have voting power, and treat us with contempt at your peril.

Expand

What are you on about? They tried giving us $9.53. Why would I want to re-invest at a price higher then market. If anyone is treating retail shareholders with contempt its Aus Super.

ORG Price at posting: $8.53 Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

MXR

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

PCK

PainChek close to finding out if FDA approves its flagship app for use in dementia care

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 53 more messages in this thread...

First 59 Last

Add ORG (ASX) to my watchlist

(20min delay)
Last $10.32		Change 0.125(1.23%)		Mkt cap ! $17.64B

Open	High	Low	Value	Volume
$10.18	$10.35	$10.14	$6.737M	656.5K

Buyers (Bids)

No.	Vol.	Price($)
11	6986	$10.31

Sellers (Offers)

Price($)	Vol.	No.
$10.32	3814	11

View Market Depth

No.	Vol.	Price($)
37	15640	10.330
21	14947	10.320
11	16966	10.310
13	30833	10.300
7	7223	10.290

Price($)	Vol.	No.
10.340	380	5
10.350	20651	20
10.360	9223	7
10.370	22147	9
10.380	18136	9

Last trade - 12.02pm 02/10/2024 (20 minute delay)

ORG (ASX) Chart

What will this fall to on failed takeover?, page-59

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

What will this fall to on failed takeover?, page-59

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News